Welcome

FSD Pharma Directors Accused of Sabotaging Its Covid Drug Trial

July 21, 2021, 7:56 PM

A FSD Pharma Inc. investor sued its controlling stockholders in Delaware, claiming they sabotaged a clinical trial of an anti-inflammatory compound showing promise in Covid-19 patients after its board declined to buy another company focused on marketing psychedelic drugs for psychiatric use.

Those “actions have needlessly, recklessly, and prematurely terminated” a “critical” drug study, forcing the company to abandon “patients lying in hospital beds being treated for Covid-19 who had agreed to participate,” the complaint says.

FSD’s controlling stockholders, Anthony Durkacz and Zeeshan Saeed, didn’t immediately respond to a request for comment Wednesday. FSD began as a cannabis company, and ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.